

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 2003/077830 A3

(51) International Patent Classification⁷: **C07H 17/00**,
A61K 31/70, A61P 33/02, 31/04, C07H 17/08

(21) International Application Number:
PCT/IB2003/000987

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 18 March 2003 (18.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P20020231A 18 March 2002 (18.03.2002) HR
60/393,612 3 July 2002 (03.07.2002) US
60/394,705 8 July 2002 (08.07.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report


(71) Applicant: **PLIVA D.D.** [HR/HR]; Ulica grada Vukovara 49, 10000 Zagreb (HR).

(88) Date of publication of the international search report:
13 May 2004

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 9-DEXO-9A-AZA-9A-METHYL-9A-HOMOERYTHROMYCIN A DERIVATIVES



$[H_2O]_x [S]_y$ (I)

(57) Abstract: Substantially pure isostructural pseudopolymorphs of 9-deoxy-9a-aza-9a-methyl-9a-homo erythromycin A having the Formula I: wherein S is an organic solvent which is at least partially miscible with water, x is 1, 1.25, 1.5 or 2, y is 0, 0.5, or 1, the pseudopolymorph being characterized by the monoclinic space group $P2_1$ and average unit cell parameters comprising: crystal axis lengths of $a = 15.5 - 17.0 \text{ \AA}$, $b = 15.5 - 17.0 \text{ \AA}$, and $c = 17.5 - 19.5 \text{ \AA}$, and angles between the crystal axes of $\alpha = \gamma = 90^\circ$ and $\beta = 106^\circ - 112^\circ$. In addition, this disclosure is directed to processes for the preparation of the substantially pure isostructural pseudopolymorphs of Formula I; to pharmaceutical compositions containing substantially pure isostructural pseudopolymorphs of Formula I; and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases by administration of a pharmaceutical composition containing the substantially pure isostructural pseudopolymorphs of Formula I.